Rein Therapeutics
Quarterly Financials
| Values in thousands | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
EBITDA | -6,375 | -5,215 | -3,870 | -5,581 |
EBIT | -6,076 | -5,838 | -32,570 | -5,492 |
Net Income | -6,375 | -5,838 | -31,967 | -5,581 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -8,640 | -3,424 | -3,220 | -3,548 |
Cash | 8,542 | 4,445 | 3,215 | 4,048 |
Basic Shares | 30,354 | 30,354 | 25,444 | 26,361 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $0 | $0 | $0 | $0 |
Gross Profit | -1 | -63 | ||
EBITDA | -50,582 | -28,049 | -15 | -27 |
EBIT | -50,583 | -28,112 | -15 | -27 |
Net Income | -49,871 | -62,883 | -15 | -27 |
Net Change In Cash | 0 | 0 | 0 | 0 |
Free Cash Flow | -19,361 | -22,291 | -19,808 | -24,865 |
Cash | 3,215 | 12,865 | 17,313 | 5,194 |
Basic Shares | 25,444 | 17,938 | 4,598 | 4,539 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-06-30 | -$0.10 |
2026-03-31 | -$0.19 |
2025-12-31 | -$1.22 |
2025-09-30 | -$0.21 |